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Better understanding of drug resistance patterns in HIV-infected children on antiretroviral therapy (ART) 
is required to inform public health policies in high prevalence settings. The aim of this study was to 
characterise the acquired drug resistance in HIV-infected children failing first-line ART in a decentralised 
rural HIV programme. 
Methods  
Plasma samples were collected from 101 paediatric patients (<15 years of age) identified as failing ART.  
RNA was extracted from the plasma, reverse transcribed and a 1.3kb region of the protease gene was 
amplified and sequenced using Sanger sequencing protocols.  Sequences were edited in Geneoius and 
drug resistance mutations were identified using the RegaDB and the Stanford, Rega and ANRS resistance 
algorithms.  The prevalence and frequency of mutations were analysed together with selected clinical 
and demographic data in STATA v11. 
Results  
A total of 101 children were enrolled and 89 (88%) were successfully genotyped; 73 on a non-nucleoside 
reverse-transcriptase inhibitor (NNRTI)-based regimen and 16 on a protease inhibitor (PI)-based regimen 
at the time of genotyping. The majority of patients on an NNRTI regimen (80%) had both nucleoside 
reverse-transcriptase inhibitor (NRTI) and NNRTI resistance mutations. M184V and K103N were the 
most common mutations amongst children on NNRTI-based and PI-based regimens. 23% had one or 
more thymidine analogue mutation (TAM) and 6% had ≥3 TAMs. Only one child on a PI-based regimen 





Whilst the patterns of resistance were largely predictable, the few complex resistance patterns seen 
with NNRTI-based regimens and the absence of major PI mutations in children failing PI-based regimens 






  1. INTRODUCTION    
By the end of 2009 there were an estimated 2.5 million (range = 1.34million) children living with the 
human immunodeficiency virus (HIV) around the world1; and approximately 340 000 children younger 
than 15 years of age were living in South Africa2. In the same year approximately 1,000 babies, per day, 
were newly infected with HIV through one of three transmission routes, namely mother-to-child 
transmission (MTCT) in-utero, during labor or delivery, and during breastfeeding (UNICEF, 2010). This 
translated to an estimated 370 000 [230 000–510 000] new paediatric HIV infections, a decline of 24% 
from the estimate of five years previously1.     
 
Without antiretroviral (ARV) treatment life expectancy among HIV-infected infants is reduced to just 2 
years3.  However, greater access to anti-retroviral therapy (ART) globally has already had a significant 
impact on survival rates and clinical outcomes4-8. In 2010, an estimated 250 000 (range=220 000-290 
000) children less than 15 years of age, died from AIDS-related causes; 20% fewer than in 20059.  In 
addition, infection rates have declined. Early ART initiation results in an up to five-fold reduced mortality 
rate and a 90% increase in survival rates among infants10.  Violari et al10 in their randomized trial of 377 
infants (6-12 weeks of age) from two major South African centre’s, namely Gauteng and Western Cape,  
(the Children with HIV Early Antiretroviral Therapy (CHER) study) reported a 76% and 75% reduction in 
mortality and disease progression rates respectively following early diagnosis and treatment initiation. 
The authors proposed ART coupled with treatment “holidays” as a feasible and practical paediatric 
management strategy, which they suggest, may become the norm in future11.  Based on this and similar 
2 
 
studies, the WHO, in 2010, amended their treatment guidelines10, 12-14 recommending ART for all HIV-
positive infants irrespective of CD4 count or clinical stage. 
 
Once children are on treatment, the cumulative risk of failure, defined as the inability to achieve or 
maintain suppression of viral replication, increases over time15 as does the likelihood of developing drug 
resistance mutations13 Drug resistance is the consequence of mutations that emerge in the viral proteins 
targeted by antiretroviral agents16. Without careful management, patients on failing regimens will 
develop not only drug resistance mutations at high prevalence rates but also accumulate resistance 
mutations if in failure for long periods.  The unfortunate consequence is that future drug choices are 
severely compromised17.  Current ARVs primarily target specific functional proteins of HIV; namely the 
reverse transcriptase enzyme targeted by RT inhibitors and the protease enzyme targeted by protease 
inhibitors, or PIs.  Mutations in these genomic regions result in conformational and functional 
adaptations that confer drug resistance to these viral variants.  ART prophylaxis as part of prevention of 
mother-to-child transmission (pMTCT) programmes, in addition, may expose infants to sub-therapeutic 
levels of ARVs such as nevirapine18. Sub-therapeutic drug levels have been associated with virological 
failure and the development of drug resistance among treated infants14.  
 
Resource–limited settings, such as South Africa pose unique challenges to the implementation of 
effective and sustainable ART programmes.  The most notable restrictions remain the limited treatment 
options available in this country, the un-availability of paediatric-friendly drug formulations and limited 
laboratory infrastructure to monitor treatment efficacy and virologic failure19. In addition, socio-
economic and psychosocial18 factors impede optimal  patient management, delay access to ARVs and 
accelerate the development of drug resistance.  Given that children have a higher risk of developing 
drug resistance, it is clear that interventions within coordinated surveillance strategies are vital to long-
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term clinical success. As a result there is an urgent need to identify patients in virological failure, and 
classify drug resistance patterns as well as levels, in a timely manner. 
 
Either genotypic or phenotypic tests to detect drug resistance mutations can guide therapeutic 
management of HIV-infected patients failing ART20.  Data on paediatric ARV resistance in South Africa, 
particularly from rural primary health care programmes in the public sector, remains limited.   This 
study, therefore, aimed to redress this imbalance in current knowledge of paediatric drug resistance in 
these resource-limited settings as a model for patient management. Towards the goal of implementing 
resistance testing on a large scale, our study investigated the spectrum and prevalence of drug 
resistance among paediatric patients within a South African Department of Health (DoH) primary health 
care facility in rural KwaZulu-Natal and the efficacy of implementing routine drug resistance testing for 
patient management as well as for research purposes.  Resistance testing of patients failing ART has 
been successfully used in adult patients in our setting21 as the system facilitates regular patient 
monitoring and routine resistance genotyping. This initiative has, in addition, yielded a cheaper, more 
accessible in-house genotyping method that may be applied at a larger public health level22, 23, as well as 
the use of resistance genotyping as both a research and clinical management tool. The same system was 








1.1   JUSTIFICATION 
Despite increased prevention strategies there will always be a proportion of children who will acquire 
HIV. Since these children as well as those that are already on treatment will require ART for the rest of 
their lives there exists a high risk of virologic failure and the development of drug resistance over time13.  
South Africa has the largest ART programme in the world with approximately 152 000 children receiving 
ARVs in 201124 This number is growing annually yet infrastructure to monitor their response to 
treatment remains limited.  Paediatric patients, under the current South African Department of Health 
guidelines (SA DoH) (Table 1), receive two nucleoside reverse transcriptase inhibitors (NRTI)22 and a non-
nucleoside reverse transcriptase inhibitor (NNTRI) or a protease inhibitor (PI). Thus the breadth of drugs 
available in this setting is severely limited.  In addition, there is currently no 3rd line option available to 
children failing both 1st and 2nd line options. This is of particular significance given the newly revised 
South African guidelines recommending ART initiation of all HIV-positive infants, at diagnosis, 
irrespective of their CD4 count or clinical stage23. The number of children on life-long ART is thus 
expected to increase significantly while children already on ART will be ageing, on treatment, into 
adolescence and adulthood. 
 
The number of current publications related to paediatric HIV drug resistance from sub-Saharan Africa is 
scant (Table 2). There is some evidence that outcomes for children in rural areas of South Africa are 
poorer than those in urban areas25. The data on ARV resistance in children in South Africa are relatively 
limited and have largely been restricted to urban hospital-based programmes, which may not be 
representative of all programmes26-32.We found only nine studies, to date, conducted in South Africa 
that used genotyping to determine the prevalence of drug resistance among children at a population 
level26-34. All these studies included HIV-1 subtype C only. Unfortunately, none of these studies consist of 
sample size greater than 50 children with the result that no reliable conclusions on resistance patterns 
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can be drawn from these data sets (Table 2). Of these studies two 28, 30 of them used in-house 
genotyping methods to assess resistance patterns in their cohorts. 
 
Our aim was therefore to add to this knowledge pool by describing the profile of drug resistance in a 
rural public health programme.  There are 1653 children currently active in the Hlabisa HIV Treatment 
and Care Programme (Personal communication: Dr James Ndirangu*) in Northern KwaZulu-Natal (KZN), 
a rural, decentralized HIV treatment programme partnered by the  Africa Centre and the SA Department 
of Health35. It has been previously reported that approximately 25% of children4, within this programme 
are vireamic i.e. do not display optimal viral suppression (VL <25 copies/ml), after 6-12 months of first-
line ART4 as has also been reported by Davies et al12 in a larger (n=6078) multi-cohort South African 
study. Since maintaining individuals on failing ARV regimens promotes the accumulation of drug 
resistance mutations and a high level of cross-resistance, it is vital that emerging resistance patterns in 
paediatric cohorts are identified early in order to safe-guard future ART regimens and ensure that 
paediatric patients will reach adulthood. Therefore the primary objective of this prospective descriptive 
study was to determine the prevalence and spectrum of resistance mutations in children failing the 







Dr James Ndirangu* is a demographer and biostatistician at the Africa Centre for Health and 
Population studies who has been actively involved in monitoring the epidemiology of HIV in 
















Table 2.    Prevalence of drug resistance mutations in South African paediatric cohorts 
 
Key: * one viral load greater than the indicated HIV copy number 
         **Two viral loads greater than the indicated HIV copy number 







HIV RNA criteria for 
genotyping 









41 >1000copies/ml* 36% 10% 71% N/A 
C 
Johannesburg33 20 >1000copies/ml* N/A 65% 65% N/A C 
Johannesburg26 41 >5000copies/ml* 44% 98% 82% N/A C 




Above detection (> 
1000copies/ml)* 
N/A 87% 78% 13% 
C 
Gauteng29 39 N/A N/A N/A N/A N/A C 
Durban31 41 N/A N/A N/A 70.7% 58.5% C 
Cape Town32 37 >1000copies/ml** 15% 23% 59% 19% C 
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1.3   AIMS OF THE STUDY 
1. To investigate and describe the prevalence and patterns of drug resistance mutations in 
paediatric patients in virological failure receiving first line ART at the Hlabisa Treatment and Care 
Programme (HTC) in rural KwaZulu-Natal, South Africa  
2. To implement and determine the utility of prospective resistance genotyping as part of patient 
management within a decentralized rural public health program. 
 
1.4   OBJECTIVES 
1. To determine the drug resistance profiles of patients within the programme using genotyping 
and bioinformatics tools. 
2. To determine the prevalence of first and second line ART failure in the Hlabisa Treatment and 













2.    Review of literature 
2.1.    Human Immunodeficiency Virus -1 (HIV-1)  
The Human immunodeficiency virus-1, responsible for >95% of the HIV epidemic worldwide belongs to 
the subclass of lentiviruses or “slow viruses”, which are characterized by a long interval between 
infection and disease development. Its 9kb RNA genome encodes nine functional proteins, Gag, Pol, Env, 
Tat, Rev, Nef, Vif, Vpu and Vpr36, capable of generating 19 gene products. These products can be divided 
into three major categories, structural and enzymatic (Pol, Gag and Env), immediate early regulatory 
(Tat, Rev and Nef), and late regulatory (Vif, Vpu and Vpr)37. The coding regions are flanked by long 
terminal repeats12 that are important in the replication of the virus.  The persistent form of the HIV-1 
genome is proviral double stranded DNA (dsDNA), which integrates into the host genome within 





                                       
 Figure 1.  Structure of Human Immunodeficiency Virus39 
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2.2.    HIV-1 Replication
 
Figure 2.   Illustration of the HIV life cycle as it occurs in the human body40 
 
The viral life cycle as depicted in Figure 2 begins when the viral membrane glycoproteins attach to the 
CD4 receptors and CCR5 or CXCR4 co-receptors of target cells.  Following attachment, there is fusion of 
the viral envelope with the cell membrane and release of the HIV capsid into the cell. Shortly after the 
viral capsid enters the cell, reverse transcriptase (RT) converts the single-stranded HIV RNA to double-
stranded HIV DNA.  The double-stranded viral DNA is carried into the host cell’s nucleus where the viral 
enzyme integrase splices the viral DNA into the host cell's chromosomal DNA.  During viral replication, 
the synthesis of the viral genome begins with the transcription of proviral DNA into mRNA. This mRNA is 
then spliced into smaller fragment, exported from the nucleus back into the cytoplasm, and translated 
into regulatory and structural proteins such as the envelope glycoprotein’s gp41 and gp120. These are 
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then transported to the plasma membrane of the host cell.  Once all components of a newly synthesised 
viral particle, including a copy of the full-length 9kb HIV genome are assembled, it buds off the host cell 
incorporating part of the cell’s membrane into its own outer membrane.  The virus then enters the 
maturation stage, where the HIV protease enzyme processes viral proteins producing a mature 
infectious virion. 
 
2.3.    Antiretroviral Drugs (ARVs) 
Currently, there is no cure for or vaccine against HIV infection; the only means of managing the disease 
is through the use of antiretroviral (ARV) drugs.  ARVs have been used to successfully manage and treat 
HIV-infected individuals since the late 1980s41 following FDA approval for the use of the first RT 
inhibitor, Zidovudine (AZT)  in 198742.  Eight years later, the FDA approved PI inhibitors for use as 
antiretroviral drugs thus expanding the options for HIV treatment and management significantly.  Later, 
with the advent of highly active antiretroviral therapy (HAART), a standard 3-drug regimen, HIV-1 
management could be approached as a chronic disease in patients who have access to medication and 
who achieve durable virologic suppression42.   
 
In recent years, significant advances in ARV therapy have been made.  Antiretroviral drugs are classified 
according to the step they inhibit in the viral life cycle. A milestone in the history of HIV disease has been 
the discovery of new classes of drugs in 1995-96 and thus introducing combination ARV therapy (HAART) 
and the gradual evolution of HIV infection into a chronic, usually non-fatal condition43. There are six 
distinct classes of drugs that target various stages of the HIV life cycle (Fig. 3).  They are the reverse 
transcriptase inhibitors, which are the nucleoside, and nucleotide reverse transcriptase inhibitors 
(NRTIs, NtRTIs) and the non-nucleoside reverse transcriptase inhibitors (NNRTIs).  In addition, ARVs 
13 
 
include the protease inhibitors (PIs), the fusion inhibitors (FIs), the entry inhibitors also known as CCR-5 
co-receptor antagonists, and the integrase inhibitors42. The current standard for a highly active ART 
regimen recommends the use of either a PI or an NNRTI in combination with two NRTIs. This is because 
the combination of multiple drugs from the same drug class decreases the potency of the regimen, for 
example three NRTIs or two NRTIs and NNRTIs will not result in optimal viral suppression. 
 
2.4.    ARVs and HIV replication 
 





2.4.1   Reverse transcriptase inhibitors 
Nucleoside analog reverse transcriptase inhibitors were the first antiretroviral drugs to be approved for 
the treatment of HIV.  The designation nucleoside analog refers to the structural similarity of these 
drugs to the building blocks (nucleotides) of nucleic acids (RNA, DNA).  While structurally similar, these 
drugs differ in that the hydroxyl (-OH) group at the 3’ position of its structure is replaced by another 
group that is unable to form the 5’to 3’ phosphodiester linkage essential for DNA elongation. Thus, 
NRTIs interfere with reverse transcriptase activity by competing with the natural substrates, become 
incorporated into viral DNA and thereby act as chain terminators in the synthesis of proviral DNA (Fig. 
4)45. Viral reverse transcriptase (RT) is the first crucial enzyme involved in HIV replication and an 
important target of antiretroviral therapy. Similar to NRTIs the NNRTIs also inhibit the synthesis of viral 
DNA. Rather than acting as false nucleotides, NNRTIs act by binding to and altering the structure of the 
RT enzyme (Fig. 3), so that it is unable to function properly46.   Of the twelve  RT inhibitors currently in 
use worldwide47, six are available in the public health sector of South Africa23 and 5 are distributed as 
child-friendly formulations (stavudine (d4T), lamivudine (3TC), zidovudine (AZT), ritonavir (RTV),  













Figure 4: An illustration of the mechanism of action of NRTI (a) and NNRTI (b) drugs showing how RT is 
disabled and thus prevents HIV from replicating  
http://www.nature.com/nature/journal/v410/n6831/fig_tab/410995a0_F3.html 
 
2.4.2   Protease inhibitors (PIs)  
HIV protease is a 99-amino-acid, aspartic acid protein and is responsible for maturation of virus particles 
into infectious virions late in the viral life cycle. HIV protease systematically cleaves individual proteins 
from the gag and gag -pol polypeptide precursors into functional subunits for viral capsid formation 
during or shortly after viral budding from an infected cell. HIV protease inhibitors function as 
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competitive inhibitors that directly bind to HIV protease and prevent subsequent cleavage of 
polypeptides (Fig. 5). They exhibit activity against clinical isolates of both HIV-1 and HIV-242 .  Currently, 
there are 9 PIs approved for use in HIV management47 and of these 5 (LPV/r and duranavir, 
fosampreanvir, ritonavir and tripanavir)48 are available in child-friendly formulations. 
 
Figure 5. An illustration of how a protease inhibitor attaches to the cleavage site and thus rendering it 
inactive. This figure also illustrates how an amino acid change in the protease inhibitor can reduce the 
affinity of the drug to the enzyme and thus the function of the enzyme is restored49 
 
 
2.4.3   Fusion / entry inhibitors 
Fusion inhibitors (FIs) were the first class of antiretroviral medications to target the HIV replication cycle 
extracellularly (before entry into a target cell) and received accelerated FDA approval in 2003. Their 
unique mechanism of action provides additional options for therapy in patients who are highly 
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treatment resistant. The use of fusion inhibitors has been limited, however, because of the production 
time and costs, limited coverage from insurance companies and HIV drug-assistance programs (HDAPs), 
complex/inconvenient drug administration (subcutaneous injection), and adverse side-effect profiles. 
Currently, enfuvirtide (Fuzeon) is the only product marketed in this class42.  
 
2.4.4    Intergrase inhibitors (IIs)  
Integrase inhibitors impede the strand transfer activity of the HIV integrase protein. Integrase catalyzes 
the process of incorporating the viral DNA into the host's chromosomes. Integrase inhibitors show 
remarkable suppression of HIV replication in treatment-naive and treatment-experienced adults, even if 
the latter is infected with an extensively drug-resistant virus. Raltegravir  (RAL) is the only approved drug 
in this class40.  It is recommended for use in children from of age.  RAL is also available in a chewable 
form suitable for children from the ages of 2-1150 it has been shown that RAL together with LPV/r may 
be a good second line option rather than LPV/r and two NRTI’s. However at its current price, it is not 
cost effective for low-middle-income countries51. There are two more IIs (elvitegravir and dolutegravir)51 
that will be entering the developed world market soon. Appendix 3 lists all the different drug classes and 
drugs that are available in these classes. 
 
2.4.5   Chemokine receptor 5 (CCR5) antagonists 
The first CCR5 antagonist maraviroc (MVC) was approved in 2007. It is the first ARV drug that does not 
bind to a viral protein but rather binds to a host protein52. The CCR5 antagonists interact with the host 
co receptor by altering its structure and thus hindering the recognition and binding of the viral gp120.  
Due to co receptor specificity the use of CCR5 antagonists are limited to patients lacking X453. Since 50%-
62% of patients that carry resistant virus, carry R5 viruses only, MVC will benefit majority of the 
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treatment experienced HIV-1 infected population. CCR5 inhibitors could be effectively used against HIV-
1 subtype C, which accounts for >50% of infections worldwide. Subtype C rarely switches to CXCR4 co 
receptor use53. 
 
2.5   Antiretroviral therapy 
 
Patients living with HIV are treated with a combination of three antiretroviral drugs from at least two 
drug classes i.e. NRTI/NNRTI/PI/II/entry inhibitors (EI). Since 1996 combination antiretroviral therapy has 
altered the course of the HIV epidemic among those living with HIV in high-income countries. However 
ART has only reached a fraction of people in low and middle-income countries, which bear 90% of the 
global HIV burden.  Access to antiretroviral therapy in low–and middle income countries increased from 
400 000 in 2003 to 6.65 million HIV-infected individuals in 2010, equating to 47% coverage of people 
eligible for treatment54.  This has resulted in substantial declines in the number of people dying from 
AIDS related causes during the past decade (Fig.6)54. The number of children receiving antiretroviral 
therapy increased from 71 500 at the end of 2005 to 456 000 in 201054. Mounting scientific evidence 
suggests that increased access to antiretroviral therapy is also contributing substantially to declines in 
the number of people acquiring HIV infection54 – a strategy termed “Treatment as Prevention”. The 
number of new HIV infections globally declined 19% over the past decade. In 15 high burden countries 
HIV prevalence declined more than 25% among young people aged 15-24 years. These declines are 










Figure 6. The UNAIDS estimates of the number of people with access to ARV therapy and the number of 









2.6   Paediatric ART in South Africa 
 
South Africa has the largest peadiatric HIV epidemic and the largest paediatric antiretroviral treatment 
(ART) programme in the world2.  According to the DoH’s most recent guidelines (2013), first-line 
paediatric ART must include two NRTIs plus a NNRTI for children older than three years or greater than 
10 kg in weight22.  Younger children (<3yrs of age) or those with a body mass <10kg require the addition 
of a protease inhibitor (PI) to the NRTI and NNRTI regimen. Unfortunately the guidelines do not specify 
recommendations for children at 3 years of age or 10kg in weight.  In these instances, the general 
practice56 is the use of body weight rather than age to guide drug choices as this ensures accurate dosing and 
prevents delivery of sub-therapeutic drug doses, which may lead to virologic failure and the development 
of drug resistance mutations14 .  As illustrated in Table 1, the choice of drugs for children failing 1st line 
ART are limited and options for those in 2nd failure are doubly scant.  This highlights the urgent need to 












Table 3. Standardised national eligibility criteria for starting ART regimens for infants and   children22 
Eligible to start ART 
 All children less than 5 years of age, irrespective of CD4 
 Children 5 years to 15b years with WHO clinical stage 3 or 4 or CD4 ≤350 cells/µl 
Require fast- track (i.e. start ART within 7 days of being eligible) 
 Children less than 1 year of age 
 WHO clinical Stage 4 
 MDR or XDR-TB 
 CD4 Count <200 cells/µl or <15% 
 
Since 2010 DoH recommends that all HIV positive children under the age of five are eligible for ART22.  In 
addition, those between 5-15 years of age at WHO clinical stage 3 or 4 or with suppressed immunity 
(CD4 count ≤350cells/μl) must be initiated immediately22 (Table 3). 
 
2.7 HIV drug resistance 
2.7.1   How does Drug Resistance develop? 
 
While studies have indicated that the introduction of HAART has altered the natural history of the HIV 
epidemic worldwide57, there remains a subset of individuals who do not recover immunologically nor do 
they suppress viral replication. In the majority of these instances, incomplete suppression invariably 
leads to the development of HIV drug resistance with significantly decreased antiretroviral efficacy57. 
While in others, virologic failure as a result of poor adherence, leads to the development of drug 




High levels of virus production and turnover characterize HIV infection. In most untreated patients, the 
total number of productively infected cells in the lymphoid tissue has been estimated to be 107 to 108 
cells. The viral population in a patient is diverse due to the highly error prone reverse transcriptase 
enzyme during the process of converting viral RNA to DNA. There is on average, one mutation for each 
viral genome that is produced, which ensures that each patient has a complex and diverse mixture of 
quasispecies, each differing by one or more mutations from another16. In addition to this rapid 
accumulation of minor genotypic changes, different HIV-1 strains can also recombine at a high rate 
generating significant genetic and phenotypic alterations. Long-term suppression requires that a 
therapeutic regimen be potent enough to suppress viral replication sufficiently to prevent rapid escape 
of mutants. However, if drug levels fluctuate or are at sub-therapeutic levels selection of drug resistant 
variants becomes inevitable in this setting of continued viral replication or insufficient suppression.  
Over time, resistance mutations may accumulate or a single mutation may develop that confer cross-














Figure 7. Selection of resistant quasispecies by sub-optimal antiretroviral therapy58 
 
2.7.2   Types of Drug Resistance 
 
There are two types of drug resistance, primary or transmitted drug resistance and secondary or 
acquired drug resistance (Fig 8). Transmitted drug resistance involves infection of a patient with an 
already resistant virus either from a partner or maternally (from mother to child). Acquired drug 
resistance is the most common type of drug resistance, which occurs as a result of mutations in the viral 
genome when HIV continues to replicate in the presence of ART58.  Resistance mutations, which occur in 
response to either drug selection pressure or genetic drift (Fig. 7), allow the virus to overcome the 
activity of ARVs to halt its replication cycle59. There are two factors that are essential for resistance to 
occur: firstly, the virus must be actively replicating so that a specific mutation can be generated and 
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allowed to outgrow the wild-type; and secondly the ARV must be present in sufficient concentrations in 
order to exert inhibitory pressure and allow replication of the resistant mutant. Sub-therapeutic drug 
levels may lead to the development of drug resistance in treatment experienced patients and has also 






Figure 8:  An illustration of the mechanism of development of acquired drug resistance (A) and 
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2.7.3   Risk factors for drug resistance 
Drug resistance has been associated with a number of risk factors that can be divided into virus related, 
drug related and host related. 
 
2.7.4   Virus related 
 Virus related factors relate to the high replication and error rate characteristic of HIV and its proteins. 
HIV produces 10 billion virions daily and during its replication cycle frequent errors are made.  This high 
mutation rate makes the virus particularly prone to the development of resistance to HAART58.  
Maintaining adequate therapeutic drug levels is thus crucial to controlling or inhibiting HIV replication. 
Several factors determine intra-patient drug levels and these include the following: 
 
2.7.5   Host related 
2.7.5.1   Adherence 
ART has been strongly correlated with HIV viral suppression, reduced rates of resistance, an increase in 
survival, and improved quality of life.  Since HIV treatment is lifelong, adherence poses a significant 
challenge and requires commitment from the patient and the health care team61. Some contributing 
factors are poor understanding of the disease and the treatment regimen, problems of getting the 
medication from the clinic, lack of social support and alcohol and other drug issues62. Other factors that 
affect children are difficulty in swallowing tablets and poor palatability of medication. Side effects also 
play a major role in non-adherence causing the patient to stop taking the medication. Some of the side 
effects are diarrhea, nausea and vomiting when taking LPV/r, AZT causes hyper pigmentation of the skin 
and nails, and ABC causes hypersensitivity syndrome and a rash63. When ARV doses are skipped or when 
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only two out of three drugs are taken at a time, this leads to inadequate drug levels in the body 64which 
is not enough to suppress the virus and thus enables it to multiply in suboptimal drug levels. 
 
2.7.5.2 Dose 
Sub therapeutic doses of ARVs can lead to drug resistance. This is of particular importance in children 
given their unique physiologies and complex pharmacokinetic profiles65.  Despite the need for careful 
and accurate dosing, information on the pharmokinetics in young children is insufficient at present66.  
Dosing in infants is challenging because drug concentrations are highly variable65. Accurate 
measurement of the dose is challenging for many caregivers as regimens for children are complicated 
involving small drug volumes, which must be adjusted as the child grows.  In addition, large volume 
liquid doses can be problematic as children do not always swallow the entire dose and sometimes spit 
some of it out65, 67.  Since children cannot swallow tablets, liquid formulations are a more favorable 
option.  Unfortunately, the number of liquid formulations is limited; they require refrigeration, which 
many high burden settings have limited access to and they are often not well tolerated68. Furthermore 
the caregiver rather than the patient is responsible for adherence to treatment, which has been shown 
to be a problem in South Africa with a high number of orphans being raised by grandparents69. Elderly 
caregivers may have poor eye-sight and have difficulty drawing up the correct volumes required. Liquid 









Adequate levels of ARVs in the bloodstream are required for the suppression of HIV replication. 
Inadequate levels allow the virus to multiply and results in the development of mutations and an 
accumulation of mutations over time71. The main problem in children is vomiting and diarrhea causing 
malabsorption of drugs.                                                                                                                                                                                                      
 
DOSAGE FORMS 
2.7.6   Drug related 
2.7.6.1   Drug-drug interactions 
Most ARVs, especially the NNTRIs and particularly the PIs have a high potential to interact with other 
medication58. There are pharmokinetic drug-drug interactions between the TB drug class of rifamycins 
and the NNRTIs and the PIs, causing decreased plasma levels of ARVs in co-infected patients72.  
ARV’s can be classified by their potency which is their ability to prevent HIV from replicating. Their 
genetic barrier to resistance is a measure of how many mutations it takes for the virus to become 
resistant to that drug64. NVP and EFV are low genetic barrier drugs and the virus only needs a single 
mutation in order to replicate73. High genetic barrier drugs such as LPV/r requires at least six mutations 
before the virus becomes resistant to it64. There is also the matter of using the CCR5 antagonist MVC 
that only target the R5 (those using exclusively CCR5 as a co receptor) tropic viruses. Using this drug 
could lead to treatment failure if there is a large percentage of X4 (those using exclusively CXCR4 as a co 







2.7.6.2   Patient related 
The widespread use of ARVs has greatly increased the level and duration of suppression of HIV 
replication. The long-term clinical and immunological success of ARVs is dependent upon strict 
adherence to the prescribed regimen. Poor drug adherence not only compromises the health of the 
patient but also threatens the health of the public with multidrug resistant HIV and widespread 
transmission of drug resistant virus18.  Adherence levels of above 95% are required in order to prevent 
the emergence and spread of drug resistant HIV variants58.  It is important to note that very slim margins 
for missed doses prior to development of resistance exist (Table 4). In addition, drug intolerance, 
toxicity, not taking drugs properly (with food, adequate liquid, etc.), the inconvenience of having to take 
ARVs, skipping doses and drug holidays may increase the chances of developing resistance.  These risks 
are amplified in resource-poor settings that hold the added challenge of proximity to primary health 
care centres, cost of transportation, drug stock outs and other socio-economic factors.   
 
Table 4.  Maximum number of doses that can be missed to still achieve ≥95% adherence62 
 
Time Interval Once daily ART regimen Twice daily ART regimen 
Last week 0   (out of 7 doses) 0-1  (out of 14 doses) 
Last 10 days 0   (out of 10 doses) 1  (out of 20 doses) 
Last month 1-2  (out of 30 doses) 3  (out of 60 doses) 








2.7.7 Drug resistance in children 
It is clear that ART for infants and children must be individualized to account for specific growth and 
developmental patterns especially in those initiated early and who survive to adolescence and 
adulthood6. ARVs are often sub-optimally dosed because of a failure to adjust for ongoing growth66. As is 
often the case, adult doses are erroneously extrapolated to children without considering potential 
differences in drug handling, age or dose requirements for effectiveness with the inevitable 
consequence of the development of drug resistance and virologic failure.   
 
Children have higher rates of virological failure than adults, often associated with more extensive 
resistance and resulting in severely limited 2nd line options6.   This is of particular concern in resource-
limited settings, such as South Africa, where the range of ARV drugs available is restricted to half the 
number of FDA approved drugs available in developed countries23, 74. There are a number of 
socioeconomic and psycho-social factors, including stigma, that also affect adherence to medication 
throughout childhood and into adolescence6. Adherence is often further compromised during 
adolescence. These problems highlight the importance of population-based surveys of drug resistance 
during childhood and adolescence. Currently only the routine tests described in Table 5 are done.  
Table 5. Routine monitoring tests in children with ART75 
Test Timing 
CD4 count and percentage At initiation 
After six months, after one year, then annually 
VL At initiation 
After six months, after one year, then annually 




Management of HIV-1-infected children will become increasingly complex as more children are initiated 
on ART and more develop extensive multiclass drug resistance. It is recommend that, rather than 
delaying until the patient is failing ART, resistance testing is performed at diagnosis and where feasible 
during treatment76. This would include all newly diagnosed children regardless of age at diagnosis and 
whether or not their mother received ART during pregnancy for pMTCT. In addition, testing should be 
conducted promptly while the patient is in virological failure76. According to the South African DoH 
guidelines, the action taken when a patient’s viral load is greater than a thousand copies/ml is to 
reinforce adherence and monitoring but does not include resistance testing (Table 6). Resistance 
mutations decrease the fitness of the virus to replicate therefore; removal of the selective drug pressure 
results in a rapid reversion of the resistant variant to become a minor variant in the viral population. 
These resistant variants may not be detected by current resistance assays. Testing is therefore 
recommended while a patient is still on therapy, while selection pressure is still being maintained77. 
 
Table 6. Viral load monitoring and recommended action75 
If child on Zidovudine, then-baseline, 1mo, 2mo, 3mo and 
then annually 
LDL cholesterol triglycerides Children on Lopinavir/ritonavir 
Annually  
ALT For a child on nevaripine, baseline, and repeat if child 
develops rash or jaundice 
Viral load (VL) Response  
<400 copies/mL 6 monthly viral load monitoring and routine adherence support 
400-1000copies/mL Repeat viral load in 6 months 
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Begin step-up adherence package if VL still between 400-1000 
>1000 copies/mL Begin step-up adherence package 
Repeat viral load in 3 months 
-If <400, return to 6-monthly 
monitoring  
-If between 400 and 1000, continue 
step up adherence and repeat VL 
after 6 months 
-If > 1000, despite stepped up 
adherence support, AND child is on a 
NNRTI-based regimen, switch to 
second-line therapy only if adherence 
is >80%. 
- If >1000 and child is on a PI-based 
regimen: 
 Reinforce adherence (it is very 
difficult to fail a PI-based 
regimen unless the child ever 
received an unboosted PI) 
 Switch to second-line therapy 
if VL > 5000, only if adherence 
is >80% and consider drug 
resistance testing if available 
-If child received an unboosted PI (eg. 
ritonavir alone) in the past, do 
resistance testing if available and 





2.8 HIV-1 Drug Resistance Testing 
HIV resistance testing has become an essential component of HIV patient management especially in 
selecting appropriately active ARVs in the setting of treatment failure. There are two types of tests for 
HIV Drug Resistance, namely phenotyping and genotyping. 
 
2.8.1   Phenotyping 
Phenotyping is an in vitro assay that measures the drug susceptibility of the viral population derived 
from an HIV-positive patient to all available ARVs. It provides a resistance index value for each drug 
which tells us the concentration of the drug that is required to inhibit viral replication by 50% (IC50)
57.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
Phenotypic assays are recombinant viral assays where relevant amplified sections of the HIV genome are 
inserted into a laboratory vector to make a replicating recombinant virus.  This recombinant virion is 
then allowed to grow following exposure to different concentrations of antiretrovirals57. Phenotypic 
testing has some advantages such as easier interpretation but it is very expensive and requires a high 
safety laboratory58 and is time consuming.  
 
2.8.2   Genotyping 
Genotypic testing involves the identification of drug resistance-associated mutations along the relevant 
segments of the viral genome. The process involves amplification of the regions of interest (example HIV 
pol, rt, env, integrase) followed by sequencing to obtain the specific nucleic acid sequence of the 
amplified products.  An example is the 99 amino acids of the protease gene and the first 300 to 400 
codons of the reverse transcriptase gene when analysed will inform on resistance mutations to PIs and 
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RT inhibitors, both drug classes currently predominantly in use77, 78. Commercial genotyping assays are 
available but are prohibitively costly particularly to resource-poor settings.  In-house assays are a more 
cost effective alternative and allow sequencing of any region of the genome in both HIV-1 and 2 and in 
different subtypes79. It is equally important to use reference sequences to take into account emerging 
resistance mutations.  Therefore, the International AIDS Society (IAS-USA) compiles a consensus list of 
mutations annually which can be accessed from their website: 
http://www.iasusa.org/resistancemutations/mutations figures.pdf (Appendices 1 and 2). 
 
2.8.3    Limitations of resistance testing 
The HIV -1 population within an individual consists of multiple variants. Often minor variants remain 
undetected while only viral variants that represent a significant percentage of the population (>10% to 
20%) will be detected by traditional sequencing techniques.  In addition, current resistance genotyping 
protocols are unable to detect “archives” or “viral reservoirs” since genotyping assays generally target 
viral RNA and not viral DNA58.  When patients failing therapy are switched to an alternate regimen, the 
mutations associated with their first failure may no longer be detectable in plasma, which is a source of 
productive viremia58. However, these archived mutations within infected cells will rebound or re-emerge 
if patients are not maintained on an appropriately suppressive regimen58. 
 
Unlike current viral load assays which are sensitive to 50 copies/ml, resistance genotyping assays are 
generally only sensitive to 500 to 1000 HIV copies /mL77. Resistance tests are therefore not useful in 





MATERIALS AND METHODS 
 
For this study, we used the affordable and open access Southern African Treatment Resistance Network 
(SATuRN) HIV-1 drug resistance genotyping system (Manasa et al. in preparation). Briefly, this is an in-
house method that costs approximately 50 US$ at reagent price. In order to keep the costs low, no viral 
load was performed before drug resistance genotyping.  A 1.3kb fragment of the protease gene was 
targeted in this assay and sequenced using Sanger sequencing and multiple primers as will be detailed 
further in this Chapter and as is illustrated in Figure 8.  This study was designed to link the rural primary 
health care clinics in the Hlabisa Treatment and Care Program with the laboratory where genotypes 













Figure 9: A flow diagram of the study design illustrating the interaction between the clinics where 
samples are collected and the laboratory where sequences are generated and analysed. 





This study was conducted in the predominantly rural Hlabisa sub-district within the uMkhanyakhude 
District of northern KwaZulu-Natal (Fig 10). The programme, delivered by the Department of Health with 
support from the Africa Centre (www.africacentre.com), has been described previously4, 24, 35.  HIV 
treatment and care is fully devolved to 16 primary health care (PHC) clinics (Fig. 10) and is delivered 
largely by nurses and counsellors, with medical officers visiting clinics on a weekly or fortnightly basis. 
 
 
Figure 10: Shows the 17 clinics (red cross) in the Hlabisa sub District where patient recruitment and 
sample collection was conducted ((http://www.africacentre.ac.za/Portals/0/Monograph%201.pdf), The 
number of patients genotyped from each clinic are indicated (blue blocks).  Twelve patients that failed 
genotyping are not indicated on the map.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
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3.2   Inclusion and Exclusion criteria 
This descriptive cross-sectional study enrolled children (≤ 15 years of age) who had been receiving ART 
for more than 12 months with evidence of virological failure, defined as two consecutive viral loads 
>1000 copies/ml.  Children with virological failure were identified from all 16 clinics (Fig. 10) both 
passively, during routine clinic visits, and actively, through interrogation of the ARTemis programme 
database (Fig 9), which is housed at the Africa Centre. Children who have had either one or two drug 
switches in their regimen prior to their enrollment in the study were included.  A medical officer 
enrolled all children.  
 
Children 16yrs and older were excluded from the study and if found to be in virologic failure were 
deferred to the adult resistance cohort, also managed by the Africa Centre.  Our analysis excluded 
children on 2nd Line ART i.e. those who have had all three drugs that they were previously on, switched. 
 
3.3 Study population: 
Basic demographic, clinical and laboratory data on all individuals initiating ART within the Africa Centre 
surveillance area are stored in the ARTemis database at the Africa Centre (Fig. 9). Children recruited into 
this study were identified in two ways: 
1.  Actively, where the ARTeMIS database of the Africa Centre was interrogated and children 
presenting with two successive viral loads >1000cp/ml were contacted for a follow-up visit. 
 
2.  Passively, where at their routine follow-up visits, and following an assessment of their charts 





A multidisciplinary team, consisting of a peadiatrician, a social worker, dietician and two members of the 
full-time resistance team, evaluated each HIV-infected patient ≤15 years, and that have been on 
treatment for more than a year, attending the primary health clinics within the sub-district, individually 
(Fig 9). Patients living near the primary family health clinic in Kwamasane (Fig 10) were transported to 
the site on a Friday. The aforementioned team of medical and clinical experts assessed and recruited 
children at their local clinics in more distant and remote locations within the sub-district. The following 
took place at the first visit, but not necessarily in this order: 
1. The counselor informed the caregivers accompanying the child, as well as the child, 
about the resistance study and gave them an information sheet (Appendix 6).  
2. The caregivers provided written informed consent (Appendices 4 and 5 ) and the 
children older than 12 years of age also provided their own written consent 
3.  A clinical information sheet (appendix 8), including details of ART drugs, a record of 
each viral load and CD4 count and possible barriers to adherence (clinical and social) 
was completed for each child recruited into the study.   
4. An infectious disease peadiatrician examined the child clinically, for routine follow-up 
and to rule out co- morbidities. 
5. A professional nurse drew a blood sample (4.5ml EDTA tube) for resistance testing. 
6. A social worker provided support to each child and their caregiver/s in order to identify 
any socio-economic factors that may be contributing to treatment failure. 
7. A dietician examined and conversed with each child and their caregiver in order to 
identify whether the household experienced food insecurity, to advise on and provide 
nutritional support and to explore the child’s normal diet and its insufficiencies as an 
impediment to treatment success. 
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8. A follow-up date was provided for the child and his/her caregiver to receive the results 
of the resistance genotyping. 
 
A social worker together with the clinician gathered details of treatment compliance from all study 
participants at each visit and adherence counseling was provided. This is in line with current national 
clinical guidelines and to determine whether treatment failure is a result of poor adherence or drug 
resistance. The information gathered at this stage afforded aid in informing on appropriate 
interventions should no resistance mutations be identified. There was no alteration in ART or 
interventions apart from those recommended by the South African DoH guidelines for paediatric HIV 
management23.  
 
3.4  Sample Size 
For this prospective study we recruited all children who were experiencing virologic failure within the 
HIV Treatment and Care Program in the uMkhanyakude sub-district. As of September 2013, the Africa 
Centre recorded a total of 28 447 patients ever initiated in the program; 8.4% of which are children less 
than or equal to 15 years of age.  The total number of children ever initiated in the program thus stands 
at 2390 but 1653 of these are currently active in the program. Of the, 1000 children that are currently 
active at 16 clinics within the sub district (Fig. 10), 101 children were included in this study.  The majority 
of the children were recruited at the Kwamsane Family Clinic, the largest and busiest clinic within the 





3.4  Africa Centre Virology Laboratory (ACVL) 
The ACVL is a molecular laboratory serving the Africa Centre in addition to conducting laboratory-driven 
research projects.  The laboratory boasts long- standing (12 years) experience in serology, HIV viral loads 
(qPCR), polymerase chain reactions (PCR) and Sanger sequencing. The ACVL has a genetic analyser (ABI 
3130xl, Life Technologies) that has been used for various applications including resistance genotyping in 
adults, TB geno-identification and sequencing of HIV env, LTR, gag and full length HIV. As such this 
facility provided the technological requirements to advance this research project. 
 
3.5   Laboratory assays 
3.5.1   Sample collection and transport 
Blood specimens, collected at the primary health care clinics, were transported from the Africa Centre in 
Mtuba to the ACVL in Durban (~200km away) on the same day of collection. Samples were received at 
the ACVL, recorded in the Laboratory information management system (LIMS) and the plasma was 
separated and stored at -80°C within 24 hours of collection, until use.   
 
3.5.2   Resistance genotyping  
3.5.2.1   RNA extraction 
Ribonucleic acid (RNA) was extracted using the Qiagen RNA Mini kit (Qiagen N.V., Venlo, Netherlands) 
according to the manufacturer’s recommendations but with the following modifications; 200µl of 
plasma was added to 800µl of lysis and 800µl Ethanol was used to precipitate the RNA prior to 
application of the mixture to the spin column.  Due to the increased volume of sample+lysis 
buffer+ethanol, addition and centrifugation of this mix to the column for RNA binding was repeated 
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twice in order to allow for maximum RNA binding. Two washes with Wash Buffer 2 were performed and 
RNA was eluted in 60µl of Buffer AVE. 
 
3.5.2.2   HIV Reverse transcription 
HIV-1 was reverse transcribed using the SuperScript® III First-Strand Synthesis kit (Life Technologies, 
Carlsbad, CA) and RT21 gene specific primer as per the protocol outlined in Table 7.  
 
Table 7. Master Mix for cDNA synthesis 
MM1 
Reagent Volume/Sample Final concentration 
Sterile Water  0.0 0 
RT21 (20mM) 0.5 0.2mM 
dNTP Mix (10 mM) 0.5 0.4mM 
Volume/Sample 1.0 
 Add 6ul of RNA to the MM1for each of the samples 
Prepare MM2 as per table below. DO NOT Aliquot this mix 
MM2 
Reagent Volume/Sample Final concentration 
10 x Buffer 1.0 1X 
MgCl (25mM) 2.0 4mM 
DTT (0.1M) 1.0 0.008M 
RNAse Out (40U/µl) 0.5 1.6U/µl 
SuperScriptIII 0.5 








Table 8. Cycling conditions for reverse transcription 
Temperature (°C) Time (min) 
65 5 
4 2 
Pause to add MM2   
50 60 
85 5 




3.5.2.3    In-House Nested PCR Method 
The cDNA generated was then PCR amplified using an optimized in-house protocol. A 1315bp fragment 
of the pol gene, covering all the 99 protease codons and the first 300 codons of the reverse transcriptase 
(RT) gene was amplified with the Platinum® Taq DNA polymerase (Life Technologies, Carlsbad, CA) and 
primers MAW26 and RT21 (Table 9) for the first step and PRO1 and RT20 (Table 9) for the second step 


























MAW-26 TTGGAAATGTGGAAAGGAAGGAC 23 Forward 




















































Water 18.4   
10 x Buffer 2.5 1 
MgCl (50mM) 1 2 
dNTP (10mM) 0.5 0.2 
MAW26 (5 pmol/ul) 0.25 0.1 
RT21 (5 pmol/ul) 0.25 0.1 
Platinum Taq 0.1 0.02 
Volume/Sample 23   
   Sample 2 
 Total Rxn Vlolume 25 
 
   2nd Round PCR 
  
 
Vol/Sample (ul) Conc/reaction 
Water 18.4   
10 x Buffer 2.5 4 
MgCl (50mM) 1 2 
dNTP (10mM) 0.5 0.2 
PRO1 (5 pmol/ul) 0.25 0.1 
RT20 (5  pmol/ul) 0.25 0.1 
Platinum Taq (5U/ul) 0.1 0.02 
Volume/Sample 23   
   
Sample 2  
Total Reaction Volume 25  
   
Cycling Conditions   
   
Temperature        Time  #cycles 
94 2min Hold 
95 30sec X 30 
58 20sec  
72 2min  


















3.6   HIV Genotyping   
HIV genome 
 
Figure 11. Diagram showing the primers covering the protease and reverse transcriptase regions 
 
Sanger sequencing was performed on successfully amplified population PCR products that were 
identified by gel electrophoresis and visualized as a 1.3kb fragment under ultraviolet (UV) light. The PCR 
products were cleaned using the PureLink® PCR purification kit (Life Technologies, Carlsbad, CA), eluted 
   
46 
 
in 35µl of elution buffer and were sequenced using the Sanger BigDye® terminator V3.1 sequencing 
protocol (Table 11), (Life Technologies, Carlsbad, CA) and four bidirectional primers (RTC1F, RTC2R, 
RTC3F, and RTC4R (Table 12), and run on an ABI 3130xl genetic analyzer (Life Technologies, Carlsbad, 
CA), finally generating a consensus sequence spanning 300 amino acids of RT and 99 amino acids of the 
protease gene.  The first 240 codons of the RT gene cover all currently recognized RT mutations 
associated with resistance to available RT inhibitors.  
 
Table 11. Master Mix for the big dye sequencing reactions 
Master Mix 
  x1 
Water 6.10 
Big Dye Ready Reaction mix 0.40 
Primer (3.20pmol/µl) 0.50 
5X sequencing buffer 2.00 
Template (20pmol/µl) 1.00 
Volume per sample 
   
 Total reaction volume 10.00 
 


















RTC1F ACCTACACCTGTCAACATAATTG 23 Forward 










RTC3F CACCAGGGATTAGATATCAATATAATGTGC 30 Forward 
RTC4R CTAAATCAGATCCTACATACAAGTCATCC 29 Reverse 
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3.7   Confirmatory HIV viral load 
Samples that failed to amplify by PCR were submitted for viral load testing using the Biocentric HIV RNA 
Charge Virale method (Biocentric, Bandol, France) with a detection limit of 50 copies/ml. A separate 
aliquot stored at -80°C is used for the viral load quantification.  Briefly this assay uses re-extracted RNA 
and is a quantitative real-time reverse transcription PCR technique targeting a conserved region within 
the LTR gene80 using MGB probes.  An internal control included in the kit confirms extraction efficiency 
and positive and negative controls are co-extracted and assayed in parallel with samples.  
 
3.8   Sequence Datasets and bioinformatics 
Sequence datasets comprised of 101 paediatric sequences, which were genotyped at the ACVL.  This 
involved the steps as explained in detail below. 
 
 
3.8.1   Sequence editing, assembling and FASTA file construction. 
Electropherograms generated by sequencing were imported into Geneious version 6.1.2 (Biomatters 
Ltd, Auckland, New Zealand), an integrated and extendable software platform for the organization and 
analysis of genomic and sequence data.  The quality of the reads was manually assessed and the ends 
trimmed to improve the quality. The trimmed reads, 4 sequences for each sample (RTC1F, RTC2R, and 
RTC3F AND RTC4R) were assembled against a Southern African subtype C reference sequence 
(Accession# 1005313). The contiguous sequence obtained from this assembly was manually edited 
checking for possible base mixtures at the major drug resistance sites. Once sequence editing was 
complete, the consensus sequence was extracted, appropriately labeled and saved in a separate folder. 
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The quality of the sequences was assessed using the HIV quality analysis tool hosted on BioAfrica.net. 
These programs provide a report of the quality of the sequence and contains information regarding the 
HIV subtype, similarities to sequences already submitted to the Genbank, the presence of stop codons 
and /or ambiguous amino acids in the sequence. Prior to the detection of DRMs using bioinformatics 
software applications, each consensus was submitted to the calibrated Population Resistance Tool (CPR) 
(http://hivdb.stanford.edu) for a final quality check. Sequences were deemed high quality if they had no 
ambiguities or insertions/deletions.  
In order to test for contamination we Blast searched our sequences against the public dataset using 
NCBI blast (http://www.ncbi.nlm.nih.gov/blast) and against our local database using the BlastServer 
application. Sequences were deemed acceptable and not contaminants if the identity was lower than 
98%. Finally, we constructed a maximum likelihood (ML) phylogenetic tree using phyML with GTR, 
gamma and percentage of invariable sites estimated from the dataset. Trees were visualized in FigTree 
(http://tree.bio.ed.ac.uk/software/figtree/) in order to identify contamination indicated by sequences 
that cluster together with low genetic diversity. 
 
3.8.2 Adding sequences with clinical information into RegaDB. 
After quality assessment the sequences were loaded onto the SATuRN database. This is a database that 
combines sequence data and clinical/patient monitoring measurements such as CD4 and Viral load as 
well as details of the patient’s ART history. The database uses three leading online drug resistance 
algorithms (ANRS 2009.07, HIVDB6.0.5, and REGAv8.0.2) to interpret the drug resistance data from the 
submitted sequence. These resistance algorithms and their mutation lists are regularly updated and 
curated.  The amino acid positions on the RT and PI genes relevant to drug resistance mutations are 
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tabulated in Table 13. Mutations were coded as DRMs at these positions based on the IAS mutation list   
of 201381.  
 
Table 13. Amino acid positions at the RT and PI genes 









Nucleoside Reverse Transcriptase inhibitors (NRTI) 
M 41* L 
A 62** V 
K 65 R 
D 67* N 
T 69 S 
K 70* R 
L 74 V 
V 75** I 
F 77** L 
Y 115 F 
F 116** Y 
Q 151** M 
M 184 V 
L 210* W 
T 215* F/Y 
K 219* Q/E 
 Non-nucleoside Reverse Transciptase Inhibitors (NNRTI) 
L 100 I 
K 101 P 
K 103 N 
V 106 M 
V 108 I 
E 138 A/G/K/Q/R 
V 179 L 
Y 181 C 
Y 188 L 
G 190 A 
H 221 Y 























F 227 C 
M 230 L 
 
Protease Inhibitors (PI ) 
D 30 N 
V 32 I 
M 46 I/L 
I 47 V/A 
G 48 V 
I 50 V 
I 54 V/L/A/M/T/S 
Q 58 E 
T 74 P 
L 76 V 
V 82 A/F/T/S 
N 83 D 
N 88 DS 
L 90 M 
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3.8.3   Drug Resistance Mutation (DRMs) Interpretation  
The effect of DRMs on treatment failure was determined using three independent drug resistance 
interpretation algorithms, which were developed at Stanford University, ANRS (French AIDS National 
Research Agency) and the REGA Institute. All of the three previous mentioned algorithms were accessed 
from RegaDB (http://www.bioafrica.net/regadb/).  
 
3.8.4   Interpretation of resistance results and clinical tests (CD4 +VLs)  
The drug resistance profile for each sequence together with the clinical data and treatment history 
(Appendix 8) of the patient’s was used to generate a drug resistance report (Appendix 7). This report 
contains drug resistance mutations identified from the patient virus and drug resistance interpretation 
based on the HIVDB version 6.0 algorithm. The report also contains genotypic susceptibility scores (GSS) 
where a GSS of 1.0 indicates drugs that are still active against the virus, 0.5 indicates drugs that have 
intermediate resistance and 0.0 is indicative of high-level resistance. A total GSS of 3 for all three drugs 
in the patient’s regimen is thus most desirable. In addition to the drug resistance information the report 
also provided the patient’s ART history, (start and stop dates for ART, ARV combinations (regimens) 
used) and CD4 and viral load histories in the form of a clinical chart. 
Once the reports were generated, they were sent to an Infectious Disease Specialist# who evaluated the 
report together with the patient’s clinical data and provided treatment recommendations based on the 
current South African guidelines.  
 
 
# ID specialists that advised over the duration of this study were:  Dr Theressa Rossouw (University of Pretoria) 
and Dr Richard Lessells (Wellcome Trust Fellow at the Africa Centre) 
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3.8.5   Querying the data from RegaDB 
The REGA database was queried using in-built parameters such as dataset names, viral isolate, 
treatment regimens and other measurements. This allowed for the compilation of smaller datasets with 
certain common characteristics. These datasets could then be analyzed using statistical programs such 
as Stata v10.0.  
 
3.9   Statistical Analysis  
In order to investigate the patterns of mutations in this cohort, the drug resistance mutations, clinical 
measurements and demographic data were exported for all patients genotyped from RegaDB for further 
statistical analysis. Descriptive statistics were used to summarize the demographic and clinical 
characteristics. Medians and the interquartile range (IQR) were calculated for continuous data and are 
quoted unless otherwise stated; in which case means (range) are presented. For analysis of drug 
resistance mutations, frequency distributions of the major DRMs were derived. The following definitions 
were used in this study:  
 Duration on ART was defined as the number of months between the date of ART initiation and 
the date of genotyping.  
 Duration of ART failure was the period in months between the date of the first viral load >1000 
copies/ml to date of genotyping, unless there was a viral load <50 copies/ml in between, in 
which cases the duration was estimated from the time of the next subsequent viral load >1000 
copies/ml. If there was no viral load ≤1000 copies/ml then duration was calculated from date of 






      RESULTS 
 
 
4.1  Study population 
 
This section presents the descriptive and basic statistics of paediatric patients recruited from 16 clinics 
within the uMkhanyakude (Fig 10).  Of the approximately 1653 children (≤15 years) who were initiated 
in and are currently active in the ART program, a total of 101 children (≤15 years of age), were identified 
as failing therapy, were enrolled between August 2011 and December 2012. These patients had been on 
ART for > 1year and presented with two or more raised viral loads (>1000cp/ml). Of the 101 patients, 89 
patients were successfully genotyped using the SATuRN genotyping method (Fig 9). The twelve samples 
that failed to amplify by PCR were subsequently submitted for viral load quantification. Viral loads 
measured indicated that seven patients had a viral load of >1000cp/ml (mean= 3.77log cp/ml; 
range=3.0-4.4 log cp/ml) at the time of genotyping but failed to amplify, while five were suppressed with 
viral loads <1000cp/ml. There was insufficient sample to perform viral load quantification for one 















Figure 12:  An illustration of the distribution of patients that were successfully genotyped compared 
to those that failed to amplify and the subsequent measures performed on the latter subset. 
 
The median duration of time between last VL result and genotyping was 3.1 months (1.4-7.0). The 
median log viral load prior to genotyping was 4.92 log cp/ml ± 5.3 (2.35-6.18log cp/ml.  Of the successful 
genotypes the median VL was 4.0 (4.7) (table 14) and the median time between last viral and sampling 









Table 14. Demographic and clinical characteristics of the 89 children with a genotype 
Characteristic Outcome  
Gender, male, n (%) 53 (59.6) 
At ART initiation 








Viral load, log10 copies/ml, median (IQR) 4.0 (4.7) 
CD4+ cell count, cells/µl, median (IQR) 
By Age category: 
0 - 2yrs (n= 3) 
>2 – 5yrs (n= 29) 





























Viral load prior to genotyping*, log10 copies/ml, median (IQR) 10.0(5.5) 
CD4+ cell count prior to genotyping*, cells/µl, median (IQR) 






d4T, stavudine; 3TC, lamivudine; EFV, efavirenz; LPVr, lopinavir/ritonavir; ABC, abacavir; AZT, zidovudine; ART, 
antiretroviral therapy; IQR, interquartile range 
* Last measurements recorded prior to date of genotype  
† Duration of antiretroviral failure was estimated from the date of the first viral load >1000 copies/ml to date of 
genotype, unless there was a viral load <50 copies/ml in-between, in which case the time was estimated from the 
next viral load >1,000 copies/ml. If there was no viral load ≤1,000 copies/ml then time was calculated from date of 
ART initiation 

















Duration of ART, years, median (IQR) 3.3 (1.9)) 
Duration of ART failure†, years, median (IQR) 1.8 (1.6) 
Time between last viral load and genotype, months, median (IQR) 3.1 (5.6) 
History of ART substitution#, yes, n (%) 12 (13.5) 
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4.2   Characteristics of patients genotyped 
This cohort was primarily male (59.6%) with a median age of 10.2 years (7.7-12.9 years) (Table 14). 
Patients had been on ART for a median time of 3.3 years (2.5-4.4).  At initiation, patients were 
predominantly on NNRTI based regimens with only 4 (4.4%) patients on the currently recommended 
(DoH, 2010) regimen for children <3yrs of age (3TC, ABC, LPV/r) and 8 (8.9%) on the currently 
recommended regimen for children over 3yrs of age (ABC, 3TC, EFV) (Table1).  We noted that most 
patients were on a failing regimen for approximately half this period of time (1.75; 03-3.4 years).  Twelve 
patients had either one or two drug substitutions in their regimens (Table 14). Of the 89 children 
genotyped, 50 (56.2%) had, on at least one occasion, successfully suppressed viraemia to <1000 
copies/ml. This would indicate that 44% of patients were unable to successfully suppress viral 
replication while on ART. The median duration on ART was slightly longer for those children on an 
NNRTI-based regimen compared to those on a PI-based regimen (3.4 years vs. 2.7 years) but the 
duration of ART failure was broadly similar between the same two groups (Table 15).  
 
 
4.3. Characteristics of patients stratified according to regimens 
 Patients on PI regimen were younger (1.5; 4.9 years) at initiation and similarly, the median age at 
genotyping was almost double in the NNRTI group (11.4; 4.4 years) than that in the PI group (5.0; 4.6 
years). We noted that age at initiation of ART (p<0.01) and at genotyping (p<0.01) was significantly 
higher in the group of children on an NNRTI-based regimen as compared to those on a PI-based regimen 
(Table 15).  In addition, CD4 counts were higher in children on a PI-based regimen at initiation (p<0.05) 
and at genotyping (p<0.01) but these clinical measurements are likely a reflection of the age, at 
imitation and genotyping, of children on a PI-based regimen (Table 16). 
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There was no significant difference in the duration on ART between patients in the NNRTI and PI groups 

























Table 15. Characteristics of children on NNRTI-based and PI-based regimens (based on regimen at time 
of genotype) 
 NNRTI (n = 73) PI (n = 16) 
At ART initiation   
Age, years, median (IQR)**                7.6 (3.1)         1.5 (4.9) 
CD4+ cell count, cells/µl, median (IQR)* 256 (369) 647 (705) 
Viral load, log10 copies/ml, median (IQR)  3.9 (4.1) 4.7 (3.6) 
At Genotyping   
Age at genotyping, years, median (IQR) 11.4 (4.4) 5.0 (4.6) 
CD4+ cell count prior to genotyping, cells/µl, median (IQR)** 379 (501) 762 (520) 
Viral load prior to genotyping,  log10 copies/ml, median (IQR)  4.3 (4.6) 4.3 (5.2) 
Comparative measures    
Duration of ART, years, median (IQR) 3.4 (1.9) 2.7 (2.4) 
Duration of ART failure, years, median (IQR) 1.8 (1.6) 1.6 (1.5) 
Time between last viral load and genotyping, months, median (IQR) 3.3 (5.5) 3.0 (3.8) 









4.4   Resistance mutations  
4.4.1   Phylogenetic reconstruction 
 
Our cohort of 89 patients who had been genotyped consisted of 73 (81.1%) patients who were on an 
NNRTI-based regimen while 16 (14.2%) were on a PI-based regimen (Table 16). All of the sequences 
accepted for analysis were deemed of high quality having passed all quality and contamination tests as 
described previously (Chapter Three). The HIV isolates from all patients successfully genotyped were 
identified as HIV-1 subtype C variants (Fig. 13). There was no evidence of contamination as each 
sequence resolved independently. 70/89 (79%) clustered with strains from South Africa (ZA). Two 
sequences clustered with strains from Malawi (PRES064 and PRES065) and 17 others clustered with 
strains from Tanzania (Fig 13).  All 89 sequences that were genotyped were not homogenous within the 
community. Sequences from each clinic did not cluster together in a discrete monophyletic branch but 





Figure 13. Maximum likelihood tree of the 89 patients that were genotyped and HIV-1 Group M 
reference sequences. Also included are representative Group N and Group P sequences.  Sequences 
generated from patients in our cohort are colour –coded according to the clinics they attended as per 
the key attached. 
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4.4.2   Overall patterns of Drug resistance mutations 
Of the 89 genotypes, 81 (91.0%) demonstrated at least one DRM while 8 (9.0%) had no DRM (Table 16).  
For those on an NNRTI-based regimen, the majority of genotypes had both NRTI and NNRTI mutations 
Thymidine analogue mutations (TAMs) were detected in 22 (23.4%) genotypes, while multiple TAMS of 
three or more were detected in four genotypes (4.5%). The Q151M complex (a multi-nucleoside 
resistance mutation) was present in two genotypes, one from a child on an NNRTI-based regimen and 
one from a child on a PI-based regimen. 
 
 
4.4.3   Patterns of Drug Resistance mutation of Patients on NNRTI-based regimens (n=73) 
Of those on an NNRTI-based regimen, 60(81.08%) had NNRTI mutations and 63 (84.14%) patients had 
NRTI mutations (Table 16). M184V was the most common NRTI mutation occurring in 60(81.08%) 
patients and K103N was the most common NNRTI mutation detected in 46 (62.16%) patients. Thirty-
nine of the 73 patients on NNRTI-based regimens (43.3%) had both the M184V and K103N mutations 
indicating resistance across drug classes. In two patients, the viral isolate sequenced harbored the Q151 
complex (Table 16). Thymidine analogue mutations (TAMs) were detected in 22 (23.40%) children of 
whom 4 had 3 or more TAMS. The D67N and T215F mutations occurred most frequently.  Multiple TAMS 
indicative of a longer duration on a failing regimen was detected in four children. Of the 22 children that 
presented with TAMs, 18 harbored the TAM pathway 2 mutations (D67N, K70R, T215F, and K219EQ). 
 
4.4.4   Patterns of Drug Resistance mutation of Patients on PI-based regimens (n=17) 
Of the 16 children that were on a PI-based regimen, only one patient harbored a PI mutation (V82A). 
Seven of the nine patients that had no DRMs were on a PI based regimen. The most common mutation 
for children on a PI regimen was the NRTI-specific mutation, M184V (Table 16).  Despite the absence of 
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PI mutations among patients on a PI-based regimen, patients in this group had a high frequency of NRTI 
(62.5%) mutations (Table 16).   
 
Table 16:  The frequency of major drug resistance mutations as well as resistance complexes associated 
with PIs, NRTIs and NNRTIs by regimen in the 89 genotyped patients prior to genotyping. 
 
 NNRTI-based regimen (n=73) PI-based regimen (n=16) 
NNRTI mutations n % n % 
Any NNRTI DRM 60 82.2 4 25.0 
L100I 5 6.9 0 0 
K101EP 6 8.2 0 0 
K103NRS 46 63.0 2 12.5 
V106M 23 31.5 2 12.5 
V108I 7 9.6 1 6.3 
Y181C 2 2.7 0 0 
Y188HCL 7 9.6 1 6.3 
ll 9 12.3 1 6.3 
P225H 14 19.2 0 0 
M230L 3 4.1 0 0 
NRTI mutations     
Any mutation 63 86.3 10 62.5 
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M41L 7 9.6 0 0 
K65NR 4 5.5 1 6.3 
D67NG 8 11.0 0 0 
K70ER 7 9.6 0 0 
L74VI 4 5.5 1 6.3 
Y115F 3 4.1 2 12.5 
M184VI 60 82.2 10 62.5 
L210W 1 1.4 0 0 
T215FYI 9 12.3 0 0 
K219QREN 5 6.9 0 0 
Any TAMS 22 30.1 0 0 
1 TAM 11 15.1 0 0 
2 TAMs 7 9.6 0 0 
3 TAMs 4 5.5 0 0 
Q151M complex 1 1.4 1 6.3 
PI mutations     
Any PI mutation 0 0 1 6.3 








Key: GSS score of 0= high level resistance; GSS score of 0.5= intermediate resistance; GSS score of 1.0= susceptible 
 
There were 65 patients that had GSS scores ≤ 1 (Table 17). This shows that almost half of the children in 
our cohort were on suboptimal regimens with perhaps 1 or two effective drugs. Thirty-seven children 
that had GSS scores ≤ 1 were on 3TC, d4T and EFV, showing that majority of the children in this regimen 
were failing ART.  
 
Of the 89 patients we have outcomes data for 73 (82%) children. The mean time between genotyping 
and follow-up was 11.6 months (range=0.06-26months).  A total of 72 children received adherence 
counseling, while 17 children were switched to a new regimen. Of the 17 children that were switched, 
16 were switched to a PI regimen and one was switched to an NNRTI regimen.  A total of 39 children 
managed to achieve viral suppression, 23 children suppressed to <25 cp/ml and 16 suppressed to < 
1000cp/ml. Fifty children were unable to achieve viral suppression following genotyping and either 
adherence counseling or treatment switch. The median VL, after a mean of 11.6months following 
genotyping (range=<1mth to 26mths), of the children that were switched was 2.4 log10 cp/ml 
(IQR=0.3log10 cp/ml) and the median CD4 was 402cells/µl (IQR=82 cells/µl).  In comparison, the median 
GSS score Number of patients Percentage  
0 8 9 
0.5 12 13.5 
1.0 45 51 
1.5 2 2.0 
2.0 10 11 
3.0 12 13.5 
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VL of the children that received adherence counseling was higher at 3.2 3log10 cp/ml (IQR=0.23log10 






















DISCUSSION AND CONCLUSION 
 
5.1   General comments 
This descriptive study presented genotyping data from one of the largest paediatric cohorts in South 
Africa.  A further novelty of the study was that all patients in this cohort were from a rural setting where 
health services are decentralized, rather than an urban setting. This study has enabled us to determine 
the prevalence and patterns of drug resistance mutations in children failing first-line ART at the Hlabisa 
Treatment and Care Programme which is a primary healthcare ART programme, in rural KwaZulu-Natal, 
South Africa. The population of Hlabisa in 2011 was 220 000, of which 83 160 were children aged 1 to ≤ 
15 years24. The area has a high burden of both HIV and tuberculosis with an estimated HIV prevalence in 
2010 of 23%24. This study was unique because it was done in a rural decentralized PHC programme 
where the delivery of ART to adults and children has scaled up rapidly.  Our study was conducted at 16 
PHC clinics, where a doctor and social worker saw all paediatric patients in order to use the genotyping 
for clinical management, as was done with adult patients (Manasa in preparation). 
 
This study has enabled us to determine the prevalence and patterns of drug resistance mutations in 
children failing first-line ART in the Hlabisa Treatment and Care Programme. The care in this facility is 
largely nurse and counsellor driven. Eighty-nine patients were genotyped in this study. We detected 
high levels of DRMs in our cohort. A total of 81 patients had at least one DRM suggesting that almost 
91% of our cohort were failing ART due to resistance and not as a result of poor adherence. Thirteen 
patients, failing their current regimen, were initiated on a previous regimen and had drug substitutions 
suggesting that they had been in virologic failure for a long period of time. Efavirenz was the only NNRTI 
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used in this cohort. It was not established if these patients were previously exposed to any NNRTI.  
However we can deduce that the older children would not have been exposed to pMTCT  since the roll 
out only started In 200382. Seventy-four children were on an NNRTI-based regimen, with the majority of 
older children on these regimens harboring drug resistance mutations. In most cases the mutations 
would be unlikely to significantly compromise a second line regimen based on a ritonavir-boosted PI.   
 
5.2   Patterns of Drug Resistance Mutations 
M184V was the most commonly occurring NRTI resistance mutation causing high-level resistance to 3TC 
and FTC, low-level resistance to ddI and ABC and increased susceptibility to AZT and d4T.  A high 
percentage (82.2%) of patients in our cohort harboured this mutation. This indicates that there was 
adherence, granted poor adherence at the time of genotyping since the M184V mutation is rapidly 
overgrown by wild-type strains in the absence of 3TC therapy. M184V is usually the first mutation to 
occur when regimens contain 3TC83. Four patients had ≥3 TAMs indicating that they were on failing 
regimens for a prolonged period. It has been shown that the length of time spent on a failing regimen 
leads to the development of complex resistance patterns84.  The factors that drive the selection of the 
TAM1 and TAM2 pathways are currently unknown. Some of these factors may include the genetic 
background of HIV-1, immune system pressure, the antiretroviral used, the sequence of drugs and 
possible pharmacokinetic parameters. Alternatively, which TAM is the first to appear might be purely 
due to chance85.  The prevalence of TAM1 seems to be higher than TAM2 in patients with less than three 
TAMs. We should also note that TAM-1 mutations are associated with an increase in phenotypic 









5.3   Previous studies 
 
One patient had the Q151M complex. These complex mutation patterns would significantly compromise 
the future activity of the NRTI class of drugs. An earlier study, done in an urban setting in South Africa, 
showed similar resistance patterns31. This study was done in Durban, KwaZulu Natal. They had a cohort 
of 94 patients. However only 41 patients were genotyped in this study. The most prevalent mutations 
that they detected were M184V (70.1%), K103N (39%) and V106M (41.5%).  These mutations were also 
the most prevalent in our study where their frequencies were 78.6%, 72% and 28% respectively.  We 
found a 24.7% prevalence of TAMs on our cohort, which was much lower as compared to the study 
done by Green et al where 39% of patients had three or more TAMs as well as to other previously 
reported investigations in other setting27, 28, 31, 34. The high prevalence of three or more TAMs was noted 
even though patients in this cohort were on ART for a shorter duration of time (median=2.8; IQR=1.9-
2.3) as compared with the patients in our cohort (median=3.3yrs; IOR=2.5- 4.4yrs). In comparison to 
these previous studies, the prevalence of mutations in our study was similar (Table 2).  Majority of these 
studies were carried out in urban settings and only one was done in a rural setting. Comparing our 
results to this rural study done in Elandshoorn, Limpopo, the prevalence of NNRTI and M184V was much 
higher than ours. However we should take into account that the number of patients in this cohort was 
much lower (n=23) as compared to ours (n=89). An additional consideration is that we may not have 
identified and recruited all patients at failure within the Africa Centre surveillance area.   
 
Our data however indicates that patients failing first line ART in our cohort should therefore remain 
susceptible to a second line regimen consisting of two alternative NRTI’s and a ritonavir-boosted PI.    
Majority of our patients (65, 74%) had GSS scores ≤1. This is an indication that they were on a 
suboptimal regimen. It is of great concern that 8 patients had a GSS score of 0 which means that none of 
the drugs in their regimens were effective. They were fully resistant to all three drugs that they were on. 
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We can speculate that this occurred due to the poor tolerability of d4T and its toxic side effect87. It was 
also noted that majority of the children that had low GSS scores were older than 3 years of age. Older 
children would not have been exposed to pMTCT and would not have been put on a PI regimen.  Most 
of the older children would have initiated ART on 3TC, d4T, EFV which was the standard starting regimen 
of the DoH before 20102. It would seem that this regimen is not ideal to start with in children given the 
high failure rates. Given that these are children who will have to remain on ART for longer compared to 
adults, it is vitally important to preserve future drug regimens especially in resource-poor setting where 
access to 3rd line drugs is limited. 
 
5.4   NNRTI’s and pMT T  
In South Africa the first line ART is largely NNRTI-based. It is challenging since drug options such as NVP 
and EFV have low genetic barriers and a single mutation can confer resistance to the entire class of 
drugs73. Both cross-resistance and high-level resistance severely compromises future ART options. A high 
percentage (72%) of patients failing ART was on NNRTI-based regimens.  In the majority of cases (80%) 
had drug resistance to both the NRTI’s and the NNRTI’s alluding to very poor outcomes. K103N was the 
most common NNRTI mutation occurring in 63% of patients, followed by V106M, which confers broad 
cross-resistance.  Exposure to NVP in pMTCT increases the risk of infection with drug resistant virus in 
infants and of treatment failure with first line regimens containing NNRTI’s82. Exposure to NVP  increases 
the risk of HIV drug resistance development in resource-limited settings73. This in turn leads to 
treatment failure of first line regimens containing NNRTI’s83, 88. It is unclear how many of the patients in 
our cohort were exposed to pMTCT however given the timing of pMTCT in the South African National 
ART program, older children in our cohort may not have been exposed to pMTCT.  The K103N mutation 
appeared in 72% of our patients.  HIV positive pregnant women that are exposed to suboptimal ART 
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often leads to selection of resistance, which is inevitably transmitted to the child89. It has been 
suggested that DRMs resulting from single dose NVP may pre-exist at low levels, even in the absence of 
NNRTI exposure. These mutants become integrated in the virus reservoir and can re- surface during 
subsequent exposure to NNRTI’s. The occurrence of NVP resistance is of particular concern because it 
confers resistance to EFV as well. Both NVP and EFV are part of the first line regimens that are used 
globally to treat both children and adults88. In this study we have not explored this and therefore cannot 
associate NNRTI mutations with single dose NVP or MTCT. 
 
5.5   PI regimens 
Only one of seventeen patients on a PI-based regimen had a major PI resistance mutation. Of the 16 
children that were on a PI based regimen, only one patient harbored a PI mutation (V82A) which was 
low as compared to previous reporting on PI mutations26, 28, 30. Since LPV/r has a high genetic barrier, this 
would explain the absence of drug resistance mutations in these patients. The younger children on PI-
based regimens more often had no drug resistance mutations (six out of 16 cases) and only one child 
had a major protease mutation. This suggests that adherence in these children was very poor such that 
there was not enough drug pressure to allow for resistance to occur. The advantage of PI’s is their high 
genetic barrier to resistance and this is especially important when adherence is a great concern73. This 
does raise the possibility of differential adherence to different components of the ART regimen (LPV/r 
syrup can be poorly tolerated), to problems with dosing of LPV/r syrup or possibly to drug-drug 






5.6    d4T- Containing regimens 
 
The majority of our patients in this cohort were on a d4T- containing regimen. Since the initial ARV scale-
up, d4t- containing regimens have been the most commonly used ARV regimens used in many national 
treatment programmes particularly in RLS due to its efficacy, short- term tolerability, low cost and its 
availability in a co-formulated form suitable for paediatric patient. 3TC and d4T were the first drugs used 
as the NRTI backbone in the treatment of children. In 2010, the World Health Organisation (WHO)90 
recommended  phasing out d4T due its potential for serious toxicity associated with long term use. This 
could explain the high rate of virologic failure in our cohort since the poor tolerability of d4T limits 
therapeutic durability and encourages poor adherence. It was noted that 52 of 58 patients on a d4T 
regimen had GSS scores ≤ 1. It is critical that first line drugs are as tolerable as possible since it is a 
patient’s best chance of achieving optimal treatment and extending treatment efficacy91. Patients will 
adhere to treatment if the drugs are tolerable and the dosing is simple eg. once daily rather that twice 
daily91. 
 
In 2010 due to the World Health Organisation recommendations, South African Guidelines replaced d4T 
with ABC due to concerns around toxicity87. Twenty-two children in our cohort who were on an ABC 
containing regimen include those that have been switched from a d4T-containing regimen. Technau87 et 
al in a recent study compared the outcomes of  ABC/ 3TC in combination with either EFV or LPV/r as 
compared to ABC/ d4T in combination with either EFV or LPV/r. Their results showed that ABC 
containing regimens had a lower probability of achieving viral suppression and higher probability of 
virological rebound than the d4T containing regimens. Adherence is a huge concern especially in 
children and since d4T has a higher genetic barrier to resistance than ABC87 , d4T is better able to deal 
with suboptimal adherence than ABC. This is of particular concern since children over three years of age 
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are being treated with ABC under the SA National HIV treatment guidelines. This may pose a problem if 
children on ABC fail to suppress within the first year of treatment and this may compromise future 
treatment options. 
 
5.7   Adherence  
Nine patients in this cohort had no DRMs yet were viraemic, strongly suggesting that they were non-
adherent or poorly adherent. The success of optimal antiretroviral therapy is directly dependent on the 
level of adherence achieved. It has been shown that in order for ART to be successful, adherence should 
be ≥95%92. Drug resistance develops very rapidly when drugs are not maintained within a therapeutic 
range. It is therefore critical that patients adhere to their complex ART regimens93. There are several 
reasons why children don’t adhere to their regimens. These include inability to swallow tablets, 
unpalatable medications and privacy issues when medication has to be administered at school or 
daycare93. There is also a problem of side effects where a child has side effects and the caregiver stops 
treatment without consulting the doctor or caregivers who think that the child is doing well and there is 
no need to continue with medication94. 
 
5.8   Poverty and HIV 
Poverty remains a serious concern globally as well as in South Africa as it impacts on the health and 
wellbeing of children95. Globally HIV is worsened by poverty. Children in South Africa, especially in our 
study area, rural KZN, are extremely vulnerable since they face both poverty and the plight of HIV. 
Peadiatric HIV is a multigenerational disease meaning that an HIV positive child may almost always have 
an HIV positive mother and/ or father95. Poverty may impact on the course of disease progression in this 
vulnerable group. Their families may be unable to access the treatment that is crucial for their wellbeing 
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and future development. Lack of funds to transport them to clinics that provide treatment or 
stigmatization by the community may prevent these families from accessing the health care that they 
require. Many families do not live within close proximity to health care facilities (fig 10) and therefore 
may not be able to access these facilities on a regular basis.  The mean distance travelled by any 
individual in our study population, to their nearest clinic is 4.72 km (maximum 13.2 km) with a median 
travel time of 81 min. Travel time to the local hospital is double this (170 min), which is more costly to 
the patient and a potential barrier to regular clinical follow-up, in addition to overburdening the referral 
centre4.  Stigma also plays a vital role in  the disclosure and treatment of children in our setting94. 
Parents or care givers are afraid to seek medical assistance or disclose their child’s status to other family 
members and as a result  the child does not get tested or does not receive the proper treatment94.  
 
5.9   Stress of orphans and caregivers 
There are a number of children who are orphans and face additional barriers to care. Orphaned children 
have to deal with economic and sexual exploitation and HIV infection as well as stigmatization and 
discrimination from their extended families96 and their community. This may lead to the emergence of 
child headed households, separation of siblings child abandonment and family breakdown96. Disclosure 
of the child’s HIV status, emotional health and reduced conflict with caregivers97 add to the stress.  
However we cannot associate non-adherence with the patients that did not have any DRMs as this was 
not investigated in our study. 
There are other added stresses that can negatively impact on HIV affected families. Families may 
experience losses of members to the disease and this adds to the psychosocial and emotional distress 
experienced by the family95.   
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It has been said that children are the hardest hit by HIV than the adult community96. In most cases their 
parents are ill or die due to the disease and the children do not have the resources to continue socially 
or economically. The majority of orphans live with their grandparents. The grandparents do not have 
sufficient resources or the strength to care for themselves and yet they have to care for their 
grandchildren. There are several challenges that these elderly guardians are faced with. Deteriorating 
mobility prevents some grandparents from accompanying their grandchildren to the clinics especially 
with the younger children that need to be carried or if they cannot walk long distances70. Some elderly 
guardians forget the child’s clinic dates and as result the child has to be without drugs for a while until 
the guardian remembers or is reminded. It is also difficult for these guardians to understand the 
complexity of the child’s regimens and this may result in the child not  taking their regimen properly at 
the proper time intervals70.   
 
 These guardians also fear that when they die there will be no one to take care of these children or 
remind them to take their medication98. This is a huge responsibility for these elderly people.  
Another reason for the lack or late treatment of children is denial of the parents in finding out the HIV 
status of the child. When a child is sick it is often ignored or the symptoms are attributed to other 
causes. Most often the child is tested after the mother has died and there is advanced disease 





5.10   ART failure 
ART failure in this population was high with a wide range of mutations. The number of children failing 
ART is of great concern. These patients are very young and will have to be on ART for the rest of their 
lives. The high prevalence of DRMs and TAMS indicate that these patients are on failing regimens for 
long periods of time without any intervention, severely compromising future drug options. There is 
therefore an urgent need for early intervention in patients that are found to be failing ART.  Failure 
could mean that these patients are not adhering and counseling can be administered or that these 
patients have DRMs and appropriate switches can be made.  Using our current genotyping system at a 
fraction of the normal cost and without a pre-genotype viral load shows that genotyping in identifying 
treatment failure can be implemented in resource limited settings like ours. This would aid in early 
intervention and management of these patients. Ideally second line drugs should be selected on the 
basis of resistance testing but the high cost thereof does not warrant this practice for routine patient 
management. In RLS where second line regimens are limited, children are likely to remain on failing 
regimens for longer periods of time, promoting the accumulation of drug resistance mutations83. We, in 
our rural cohort, also demonstrated the presence of complex resistance patterns in patients failing 
therapy and who had been on a failing regimen for a median of 1.75 years (03-3.4).  The number of 
drugs available in South Africa is limited and there is currently no 3rd line option available to children 
failing therapy. It is therefore important to determine emerging resistance patterns in paediatric 
patients to ensure that children continue to receive appropriate ART regimens. Children have a higher 
risk of developing drug resistance and it is therefore clear that interventions within coordinated 






5.11   Cost of genotyping 
The current cost of our genotyping reagents are approximately 50US$ at reagent cost and less than 
100US$ when staff and transport costs are added. In the public sector, including in South Africa, the cost 
of genotyping is 250-300US$ and largely prohibitive to the vast majority of patients receiving treatment. 
In order to perform large-scale genotyping and in the interest of reducing costs, we did not do a pre-
genotype viral load yet we successfully genotyped 88% (89/101) of patients in our cohort. Our 
genotyping system is open source. Any molecular laboratory can perform this assay as it requires 
routine equipment that can be found in any molecular laboratory. However not all laboratories may 
have a sequencer. Perhaps the preliminary work can be done and this could be sent to a central 
laboratory for sequencing. The analysis software is also open access and very user friendly. This system 
has worked quite well for us as we were able to provide results i.e. sequence the samples, analyze them 
and produce reports within a specific turnaround time so that the clinician could get feedback and thus 
manage the patient appropriately. Genotyping is not routinely done to guide clinicians on the 
management of patients that are failing ART.  Clinicians are generally reluctant to switch patient’s drugs 
or regimens and they use clinical markers such as CD4 and viral load before making that decision.  
However with our cheaper and much more affordable genotyping system, management and guidance of 
failing patients could become easier for clinicians so that patients will not remain on failing regimens for 







Table 18.  Comparison of commercial genotyping assays and the SATuRN in-house genotyping method 
Parameter  ViroSeq  TruGene  
SATuRN  
In-house method 
Subtypes  Subtype B (FDA approved), non-B  Subtype B (FDA approved), non-B  Major Group M viruses  

























The SATuRN genotyping system is likely to be affordable (Table 18) to upper middle-income countries 
like South Africa and Botswana but further cost reductions would be required to make drug resistance 
testing affordable in lower middle-income and low income countries within Africa. This may be possible 
in the near future given the industry trends of significant reduction in sequencing costs that have been 
observed over the past 5 years. The added feature of pooling patient samples that is currently possible 
for next generation sequencing further reduces sequencing costs for individual patients.  An additional 
feature of our study was that genotypes directed subsequent clinical care where a doctor, social worker 
and other clinic staff managed patients from enrolment to implementing an intervention post-
genotyping as was carried out on an adult cohort from the same area99. Of the 89 patients that were 
genotyped, 39 patients managed to suppress their VL to ≤1000cp/ml and of these 23 patients 
suppressed to ≤25cp/ml. Seventeen patients were switched to 2nd Line regimens and this switch was 
motivated and guided by the genotyping result.  In this way individualized treatment is enabled even in 




5.12   Limitations 
Although the number of patients in our cohort was larger than previous studies conducted in South 
Africa, the number is still fairly small relative to the number of infected children and those on treatment 
in the country. Future studies should look at larger cohorts including pooling of data and related 
surveillance from different sites in order to inform national policies. This was a cross sectional study 
where we identified as many children as possible that were experiencing virologic failure but we are not 
certain that all the children that were eligible were included in this study. We are however certain that 
patients who had been failing at the time of the study and who attended any one of the 17 clinics in our 
surveillance area were recruited.  Approximately 1653 children were active in the ART programme. We 
only identified 101 patients that were failing. However the failure rate in this area was previously 
described as being approximately 25%. In this study we only managed to recruit 6% of patients that 
were failing therapy.  In this study we did not determine whether the DRMs’s detected in the children 
were acquired or transmitted resistance.  Perhaps this can be explored in future analysis of this cohort. 
We had only one patient that had a PI mutation as we only looked at the protease gene. It is possible 
that we could have missed mutations at other sites, eg. Gag cleavage sites100 and env. Although HIV 
resistance to PIs results from the selection and accumulation of mutations in protease, other genomic 
regions could be involved in PI resistance.101 Several studies have shown that gag and gag-pol cleavage 
sites might influence the virological outcome of a PI-based regimen101, 102. As previously mentioned, the 
impact of pMTCT was not investigated in this study but given the delayed rollout of the ART program as 
a whole in the country and in this region, we estimate that the majority of children older than 10years of 
age (n=47) in our study will not have been exposed to combination pMTCT regimens either during 
gestation or breastfeeding.  Their exposure to single-dose nevirapine is highly likely but previous studies 
have demonstrated the disappearance of any associated mutation within a year103.   
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5.13   Conclusion  
In conclusion, this study has demonstrated that the spectrum of drug resistance mutations in this rural 
cohort is complex and varied.  The concerning prevalence of high-level resistance mutations particularly 
the frequency of TAMs amongst this paediatric cohort is an indicator of the time these patients spent on 
a failing regimen.  This highlights the need for timely identification of patients failing ART and the 
implementation of early interventions, be it drug switches or effective, reinforced, adherence counseling 
with appropriate follow-up. The results from our study addressed three of the ten goals of the 
Department of Health 2013 ART Guidelines22. We presented a means of achieving the best outcomes for 
HIV patients receiving ART in a cost-effective manner (Goal B), we used an existing infrastructure for 
patient management (Goal D), that of a decentralized rural public health clinic facility and we identified 
DRMs early which ensured patient retention on lifelong ART by early interventions to stop ART failure 
and prevent mortality and morbidity of our patients (Goal I). In resource limited settings there are few 
available ART options. This study provides compelling arguments for the recommendation that a 
genotype be performed on all patients failing ART91, 104. This aids in deciding whether a patient’s regimen 
should be switched due to the presence of mutations and prevent unnecessary switching in the absence 
of mutations. More importantly, genotyping allows for individualized patient care thereby preserving 
the remaining spectrum of drugs within the program for future use. Genotyping is very expensive and is 
not routinely performed in resource-limited settings. However we have shown that genotyping can be 
performed at a fraction of the current cost and can be made freely accessible in settings similar to ours.  
All laboratory and analysis protocols used in this study are open source, further reducing costs.  Thus we 
propose that there are currently few restrictions to implementing resistance genotyping for patient 
management at any public health setting including remote rural areas such as in our investigation.  
Given the spectrum and frequency of complex, high-level resistance mutations we observed, such a 
management strategy must urgently be considered for successful patient management. 
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Older treatment programmes in Africa reveal complex resistance patterns105. Despite being one of the 
younger ART programs in the world, we noted complex resistance patterns with DRMs at high 
frequencies and this may be a reflection of the enormity of the South African ART program and the fact 
that freely available and widespread distribution of ART often results in the widespread emergence of 
drug resistance105. Although the rate of TR is low (<5%)99 currently,  mathematical modeling suggest that 
this rate could increase considerably in the next ten years106. The impact of TR in children could be 
greater as the path from drug resistance to virologic failure, immunologic failure and death occurs much 
faster than in adults106. It is therefore imperative that children are managed effectively and that timely 
interventions be instituted in order to maintain them on long term ART since the possibility of a vaccine 




































Antiretroviral drug class 
 
Abbreviations First approved to 
treat HIV 









NRTIs interfere with the action of an HIV 
protein called reverse transcriptase, which the 
virus needs to make new copies of itself. 
 
Lamivudine and zidovudine(Combivir) FTC, 
emtricitabine (Emtriva) lamivudine, 3TC (Epivir) 
abacavir/ lamivudine (Epzicom) zalcitabine, ddC, 
dideoxycytidine (Hivid) zidovudine, AZT, 
azidothymidine, ZDV (Retrovir) abacavir, zidovudine, 
and lamivudine (Trizivir) tenofovir 
disoproxil/emtricitabine (Truvada) enteric coated 
didanosine (Videx EC) didanosine, ddI, dideoxyinosine 
(Videx) tenofovir disoproxil fumarate (Viread) 
stavudine, d4T (Zerit) abacavir, ABC (Ziagen 
Non-Nucleoside Reverse 




NNRTIs also stop HIV from replicating within 
cells by inhibiting the reverse transcriptase 
protein.  
 
Delavirdine  DLV, (Rescriptor),   
efavirenz(Sustiva),nevirapine (Viramune) 




PIs inhibit protease, which is another protein 
involved in the HIV replication process.  
 
Amprenavir (Agenerase),Tipranavir (Aptivus) 
saquinavir mesylate, SQV (Invirase) lopinavir and 
ritonavir (Kaletra), Fosamprenavir Calcium (Lexiva) 
ritonavir, ABT-538 (Norvir),  darunavir (Prezista),  
atazanavir sulfate (Reyataz) nelfinavir mesylate, NFV 
(Viracept) 
Fusion or Entry 
Inhibitors  
 2003 
Fusion or entry inhibitors prevent HIV from 
binding to or entering human immune cells.  
 
enfuvirtide, T-20 (Fuzeon), maraviroc  
Integrase Inhibitors  
 
2007 
Integrase inhibitors interfere with the integrase 
enzyme, which HIV needs to insert its genetic 
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